Heart Attack (Myocardial Infarction) Clinical Trials

"THE VERTIS CV STUDY" Type 2 Diabetes Mellitus and Established Vascular Disease Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes http://www.mercknewsroom.com/news-release/corporate-news/merck-and-pfizer-announce-two-pivotal-phase-3-studies-ertugliflozin-inve

WHAT IS THE SPIRE PROGRAM? The SPIRE program is a series of clinical studies that is investigating a study drug in people who have high cholesterol. This study drug is being evaluated to understand its effects on bad cholesterol (LDL-C) and cardiovascular events such as heart attack or stroke. The ...

1. Background 1.1. Antiplatelet therapy after acute myocardial infarction Dual antiplatelet therapy with aspirin, combined with a P2Y12 receptor inhibitor, is a cornerstone of therapy for acute myocardial infarction (AMI). Treatment with clopidogrel in addition to aspirin resulted in a 20% reduction in major adverse cardiovascular events (MACE) when compared ...

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of a Research Medication in Reducing the Occurrence of Major Cardiovascular Events

The THEMIS clinical research study is evaluating a study drug to see if it may help prevent heart attack and stroke in people with type 2 diabetes.

Announcing a new research study of nutritional supplements Specifically, the study will examine whether certain supplements can reduce readmission rates in adults >65 years of age who are hospitalized for the following diagnoses: Heart attack Heart failure COPD Pneumonia

People with these conditions have a higher risk of heart attack or stroke in the future. Because we know who is at a greater risk, we want to take early steps to try to prevent a cardiovascular emergency. The Aleprevent clinical research study will look at whether an investigational medication ...

Have you been told that you have or that you are at risk for developing Heart Disease? If you are 45 years of age or older and have high triglyceride levels, you may be eligible to participate in a clinical research study evaluating the safety and effectiveness of an investigational ...

The treatment options this study will compare are: (1) Hybrid Coronary Revascularization [HCR] (a combination of surgery and catheter procedures to open up clogged heart arteries) and (2) Percutaneous Coronary Intervention [PCI] (catheter procedures alone to open up clogged heart arteries). There are no new or "experimental" procedures being tested ...

Inflammatory processes have been identified as key mediators of ischemia/ reperfusion injury in ST-segment elevation myocardial infarction. They add additional damage to the myocardium and are associated with clinical adverse events (heart failure and cardiovascular death) and poor myocardial recovery. All the different anti-inflammatory approaches to reduce reperfusion injury have ...